Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pinter

Showing results (71-80 of 135) with videos related to

Pageof 14
Sort By:
BMJ Open|September 14, 2021
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)Kilian Eyerich, Peter Weisenseel, Andreas Pinter, et al.
Dermatology and Therapy|July 23, 2025
Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)Andreas Pinter, Alan Brnabic, Emanuele Trovato, et al.
Advances in Therapy|January 9, 2024
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic DermatitisAmy S Paller, Andreas Pinter, Lara Wine Lee, et al.
Dermatology and Therapy|March 4, 2021
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot StudyUlrich Mrowietz, A David Burden, Andreas Pinter, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
Advances in Therapy|June 18, 2023
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16Jacob P Thyssen, Marjolein de Bruin-Weller, Antonio Costanzo, et al.
Life (Basel, Switzerland)|October 27, 2022
Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBestNatalia Kirsten, Frenz Ohm, Kathrin Gehrdau, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Acta Dermato-Venereologica|March 6, 2025
Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HSNatalia Kirsten, Matthias Augustin, Christine Blome, et al.
Pageof 14

Showing results (71-80 of 135) with videos related to

Sort By:
Pageof 14
BMJ Open|September 14, 2021
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)Kilian Eyerich, Peter Weisenseel, Andreas Pinter, et al.
Dermatology and Therapy|July 23, 2025
Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)Andreas Pinter, Alan Brnabic, Emanuele Trovato, et al.
Advances in Therapy|January 9, 2024
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic DermatitisAmy S Paller, Andreas Pinter, Lara Wine Lee, et al.
Dermatology and Therapy|March 4, 2021
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot StudyUlrich Mrowietz, A David Burden, Andreas Pinter, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
Advances in Therapy|June 18, 2023
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16Jacob P Thyssen, Marjolein de Bruin-Weller, Antonio Costanzo, et al.
Life (Basel, Switzerland)|October 27, 2022
Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBestNatalia Kirsten, Frenz Ohm, Kathrin Gehrdau, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Acta Dermato-Venereologica|March 6, 2025
Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HSNatalia Kirsten, Matthias Augustin, Christine Blome, et al.
Pageof 14